Welgene BiotechLtd Balance Sheet Health
Financial Health criteria checks 4/6
Welgene BiotechLtd has a total shareholder equity of NT$298.4M and total debt of NT$121.1M, which brings its debt-to-equity ratio to 40.6%. Its total assets and total liabilities are NT$512.9M and NT$214.4M respectively.
Key information
40.6%
Debt to equity ratio
NT$121.14m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$201.29m |
| Equity | NT$298.45m |
| Total liabilities | NT$214.43m |
| Total assets | NT$512.88m |
Recent financial health updates
No updates
Recent updates
Is Welgene Biotech Co.,Ltd.'s (GTSM:6661) 4.7% Dividend Sustainable?
Mar 19
Are Welgene BiotechLtd's (GTSM:6661) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 10
Welgene Biotech Co.,Ltd.'s (GTSM:6661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 13Know This Before Buying Welgene Biotech Co.,Ltd. (GTSM:6661) For Its Dividend
Dec 10Financial Position Analysis
Short Term Liabilities: 6661's short term assets (NT$296.3M) exceed its short term liabilities (NT$112.7M).
Long Term Liabilities: 6661's short term assets (NT$296.3M) exceed its long term liabilities (NT$101.7M).
Debt to Equity History and Analysis
Debt Level: 6661 has more cash than its total debt.
Reducing Debt: 6661's debt to equity ratio has increased from 12.7% to 40.6% over the past 5 years.
Debt Coverage: 6661's debt is well covered by operating cash flow (32.3%).
Interest Coverage: Insufficient data to determine if 6661's interest payments on its debt are well covered by EBIT.